his summary describes a study of a new pill for treating chronic heart failure called empagliflozin (brand name Jardiance®). The study is called EMPEROR-Preserved and was published in the New England Journal of Medicine. Chronic heart failure is a condition where the heart does not pump blood around the body properly. Heart failure causes symptoms such as shortness of breath, tiredness and build-up of too much water in the body (fluid retention). These symptoms often need hospital treatment and increase the risk of early deathThis Plain Language Summary of Publication article from Future Cardiology describes how a medication called empagliflozin works in people living with a type of heart failure called heart failure with preserved ejection fraction, this is when the lower left chamber (ventricle) of the heart is too stiff to fill with enough blood during each heartbeat.

Visit the Future Medicine site using the link to read the full article.

The original article on which this summary is based is called ‘Empagliflozin in heart failure with a preserved ejection fraction’ and was published in The New England Journal of Medicine. 

Visit The New England Journal of Medicine site using the link to read the article.